Indirect data from systematic reviews or meta-analyses, mostly in NSCLC, are inconsistent with those from some studies showing no difference in efficacy between PD-1 or PD-L1 antibodies and from others indicating improved survival in favor of PD-1 inhibitors (212–214). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.